Ironwood Pharmaceuticals Inc. IRWD

What this company does

LINZESS (linaclotide), its commercial product, is the first product approved by the U.S. Food and Drug Administration in a class of GI medicines called guanylate cyclase type C agonists, indicated for the treatment, in the U.S., of irritable bowel syndrome with constipation in adults and pediatric patients 7 years of age and older, chronic idiopathic constipation in adults, and functional constipation in pediatric patients ages 6-17 years old. LINZESS is also available for the treatment of adults with irritable bowel syndrome with constipation or chronic idiopathic constipation in Mexico, adults with irritable bowel syndrome with constipation or chronic constipation in Japan, and adults with irritable bowel syndrome with constipation in China, while linaclotide is available under the name CONSTELLA in Canada and in certain European countries. It was incorporated in Delaware on January 5, 1998 as Microbia, Inc., and on April 7, 2008 changed its name to Ironwood Pharmaceuticals, Inc. As of December 31, 2025, it had 100 employees, of whom 66 were on its drug development team and 34 were in selling, general and administrative functions.

Written from the business description in IRONWOOD PHARMACEUTICALS INC's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.